Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
lundquist.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
68
Active
5
Phase 3
7
Total enrollment
14,267
Pipeline matrix
Showing 15 of 15 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Epidiolex | — | — | — | — | — | 1 | |
| Saline Solution for | — | — | — | — | 2 | ||
| Adalimumab Injection [Humira] | — | — | — | — | — | 1 | |
| Omadacycline Pill | — | — | — | — | — | 1 | |
| Standard of Care | — | — | — | — | — | 1 | |
| Hydrocortisone | — | — | — | — | — | 2 | |
| Ketoconazole Pill | — | — | — | — | — | 1 | |
| Ganirelix | — | — | — | — | — | 1 | |
| Dexamethasone Pill | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | — | 1 | |
| Cosyntropin Injectable Product | — | — | — | — | — | 1 | |
| Recombinant Human Luteinizing Hormone | — | — | — | — | — | 1 | |
| Gonadorelin | — | — | — | — | — | 1 | |
| Corticorelin | — | — | — | — | — | 1 | |
| Saline Solution | — | — | — | — | — | 1 |
Next readouts
- 2022-07-24
- 2026-02
- 2027-01
- 2027-04
Top conditions
- Endothelial Dysfunction3
- Atherosclerosis3
- Pulmonary Arterial Hypertension2
- Inflammation2
- Mucopolysaccharidosis I2
- Mucopolysaccharidosis II2
- Mucopolysaccharidosis VI2
- End-Stage Renal Disease2
Frequently asked questions about Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- How many clinical trials does Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center have on ClinicalTrials.gov?
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is listed as the lead sponsor on 68 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's trials are in Phase 3?
- 7 of Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's trials are in Phase 3, spread across 15 active drug programs.
- What therapeutic areas does Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center focus on?
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's most-studied conditions on ClinicalTrials.gov are Endothelial Dysfunction, Atherosclerosis, Pulmonary Arterial Hypertension, Inflammation, Mucopolysaccharidosis I.
- When are Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's next clinical trial readouts?
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center has 4 upcoming primary-completion readouts tracked here; the soonest is “Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women”, expected around 2022-07-24.